Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

S Novello, J Mazières, I-J Oh, J de Castro, M R Migliorino, Å Helland, R Dziadziuszko, F Griesinger, A Kotb, A Zeaiter, A Cardona, B Balas, H K Johannsdottir, A Das-Gupta, J Wolf, S Novello, J Mazières, I-J Oh, J de Castro, M R Migliorino, Å Helland, R Dziadziuszko, F Griesinger, A Kotb, A Zeaiter, A Cardona, B Balas, H K Johannsdottir, A Das-Gupta, J Wolf

Abstract

Background: This is the first trial to directly compare efficacy and safety of alectinib versus standard chemotherapy in advanced/metastatic anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) patients who have progressed on, or were intolerant to, crizotinib.

Patients and methods: ALUR (MO29750; NCT02604342) was a randomized, multicenter, open-label, phase III trial of alectinib versus chemotherapy in advanced/metastatic ALK-positive NSCLC patients previously treated with platinum-based doublet chemotherapy and crizotinib. Patients were randomized 2 : 1 to receive alectinib 600 mg twice daily or chemotherapy (pemetrexed 500 mg/m2 or docetaxel 75 mg/m2, both every 3 weeks) until disease progression, death, or withdrawal. Primary end point was investigator-assessed progression-free survival (PFS).

Results: Altogether, 107 patients were randomized (alectinib, n = 72; chemotherapy, n = 35) in 13 countries across Europe and Asia. Median investigator-assessed PFS was 9.6 months [95% confidence interval (CI): 6.9-12.2] with alectinib and 1.4 months (95% CI: 1.3-1.6) with chemotherapy [hazard ratio (HR) 0.15 (95% CI: 0.08-0.29); P < 0.001]. Independent Review Committee-assessed PFS was also significantly longer with alectinib [HR 0.32 (95% CI: 0.17-0.59); median PFS was 7.1 months (95% CI: 6.3-10.8) with alectinib and 1.6 months (95% CI: 1.3-4.1) with chemotherapy]. In patients with measurable baseline central nervous system (CNS) disease (alectinib, n = 24; chemotherapy, n = 16), CNS objective response rate was significantly higher with alectinib (54.2%) versus chemotherapy (0%; P < 0.001). Grade ≥3 adverse events were more common with chemotherapy (41.2%) than alectinib (27.1%). Incidence of AEs leading to study-drug discontinuation was lower with alectinib (5.7%) than chemotherapy (8.8%), despite alectinib treatment duration being longer (20.1 weeks versus 6.0 weeks).

Conclusion: Alectinib significantly improved systemic and CNS efficacy versus chemotherapy for crizotinib-pretreated ALK-positive NSCLC patients, with a favorable safety profile.

Trial registration: ClinicalTrials.gov NCT02604342; Roche study MO29750.

Figures

Figure 1.
Figure 1.
Patient disposition in the ALUR study. C-ITT, patients in the ITT population with CNS disease at baseline; CNS, central nervous system; FTP, first treatment period; ITT, intent-to-treat; mC-ITT, patients in the ITT population with measurable CNS disease at baseline.
Figure 2.
Figure 2.
PFS in the intent-to-treat population. (A) PFS by investigator assessment, (B) PFS by Independent Review Committee assessment, and (C) subgroup analysis of investigator-assessed PFS. CI, confidence interval; NE, not evaluable; PFS, progression-free survival.
Figure 3.
Figure 3.
Cumulative incidence of CNS progression, non-CNS progression, and death in: (A) the ITT population, (B) the C-ITT population, and (C) patients in the ITT population without CNS disease at baseline. CI, confidence interval; C-ITT, patients in the ITT population with CNS disease at baseline; CNS, central nervous system; ITT, intent to treat; NE, not evaluable.

References

    1. Chun SG, Choe KS, Iyengar P. et al. Isolated central nervous system progression on crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation? Cancer Biol Ther 2012; 13(14): 1376–1383.
    1. Costa DB, Shaw AT, Ou SH. et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 2015; 33(17): 1881–1888.
    1. FDA Approval for Ceritinib. (March 2018, date last accessed).
    1. EMA Zykadia recommended for approval in advanced nonsmall-cell lung cancer. (March 2018, date last accessed).
    1. Stenger M. Ceritinib in ALK-positive metastatic NSCLC patients with progression on or intolerance to crizotinib. The ASCO Post 10 June 2014, Volume 5, Issue 9. (March 2018, date last accessed).
    1. Zykadia™ (ceritinib) USPI, April 2014. (March 2018, date last accessed).
    1. Ou SH, Ahn JS, De Petris L. et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 2016; 34(7): 661–668.
    1. Shaw AT, Gandhi L, Gadgeel S. et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 2016; 17(2): 234–242.
    1. Peters S, Camidge DR, Shaw AT. et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 2017; 377(9): 829–838.
    1. FDA Approval for Alectinib. (March 2018, date last accessed).
    1. European Medicines Agency (EMA). European public assessment report (EPAR) for Alecensa. ; February 2017. (March 2018, date last accessed).
    1. Roche media release. (March 2018, date last accessed).
    1. Roche media release. (March 2018, date last accessed).
    1. Gadgeel SM, Shaw A, Govindan R. et al. Pooled analysis of CNS response to alectinib in two studies of pre-treated ALK+ NSCLC. J Thorac Oncol 2015; 10(Suppl 2): abstract 1219.
    1. Hida T, Nokihara H, Kondo M. et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 2017; 390(10089): 29–39.
    1. Johung KL, Yeh N, Desai NB. et al. Extended survival and prognostic factors for patients with ALK-rearranged non–small-cell lung cancer and brain metastasis. J Clin Oncol 2016; 34(2): 123–129.
    1. Zhang I, Zaorsky NG, Palmer JD. et al. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol 2015; 16(13): e510–e521.
    1. Guerin A, Sasane M, Wakelee H. et al. Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy. Curr Med Res Opin 2015; 31(8): 1587–1597.
    1. Ou SH, Jänne PA, Bartlett CH. et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 2014; 25(2): 415–422.
    1. Solomon BJ, Mok T, Kim D-W. et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371(23): 2167–2177.
    1. Shaw AT, Kim TM, Crinò L. et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2017; 18(7): 874–886.
    1. NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines), Non-Small Cell Lung Cancer, version 9.2017, October 17, 2017. (March 2018, date last accessed).

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する